Abstract Germline DICER1 mutations have been described in individuals with pleuropulmonary blastoma (PPB), ovarian Sertoli-Leydig cell tumor (SLCT), sarcomas, multinodular goiter, thyroid carcinoma, cystic nephroma and other neoplastic conditions. Early results from the International Ovarian and Testicular Stromal Tumor Registry show germline DICER1 mutations in 48 % of girls and women with SLCT. In this report, a young woman presented with ovarian undifferentiated sarcoma. Four years later, she presented with SLCT. She was successfully treated for both malignancies. Sequence results showed a germline intronic mutation in DICER1. This mutation results in an exact duplication of the six bases at the splice site at the intron 23 and exon 24 junction.
Introduction
Germline DICER1 mutations were first identified in children with pleuropulmonary blastoma (PPB), a rare but aggressive lung tumor of infancy and early childhood [1, 2] . Conditions which are now known to be associated with germline DICER1 mutations include PPB, Sertoli-Leydig cell tumor (SLCT), cystic nephroma, lung cysts, nodular hyperplasia and/or carcinoma of the thyroid gland, nasal chondromesenchymal hamartomas, embryonal rhabdomyosarcoma of the uterine cervix, ciliary body medulloepithelioma, renal sarcoma, pituitary blastoma, Wilms tumor and pineoblastoma [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . DICER1 encodes an RNase III endonuclease which cleaves precursor microRNAs into active microRNAs. Most tumors in DICER1 syndrome have one allele (often germline) harboring a nonsense or frame-shift mutation predicted to cause full loss of function (LOF) with the other allele harboring a missense mutation in the DICER1 RNase IIIb domain. This combination of mutations in both DICER1 alleles results in improperly cleaved 5p miRNAs from the pre-miRNA hairpin structures, leading to an abnormal ratio of 5p:3p miRNAs and altering expression of downstream target mRNAs [4] . Data from the International Ovarian and Testicular Stromal Tumor (OTST) Registry indicate that almost half of children and adults with SLCT have germline DICER1 mutations [20] . We have also found biallelic somatic mutations in children with ovarian SLCT in absence of a germline mutation (unpublished OTST Registry data presented at Children's Oncology Group 2014 Fall Meeting). Here we report two young women with SLCT both of whom have a unique intronic loss of function germline mutation in DICER1 and tumor-specific RNase IIIb missense mutations.
Materials and methods
Eligible participants with a history of ovarian or testicular stromal tumors were enrolled in the International OTST Registry (www.OTSTregistry.org). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all participants or proxy caregivers. Additional written consent for this specific publication was provided by Patient #1 whose unique clinical history poses a potential for identification. This article does not contain any studies with animals performed by any of the authors. The participants described in this report were tested for germline DICER1 mutations using previously described methodology [21] . Initial testing for DICER1 mutations was performed by standard Sanger methods as described previously or by a commercial laboratory (Ambry Genetics, Aliso Viejo, CA). Somatic testing on formalin-fixed paraffin embedded tumor tissue as previously described [21] .
Results
A 10 year old girl presented with a 1 month history of dysuria and pelvic pressure. She underwent exploratory laparotomy and left oophorectomy. Pathology showed an undifferentiated sarcoma with limited myogenic phenotype (Fig. 1) . The tumor was characterized by moderately atypical spindle cells in a fascicular pattern with a myxoid stroma and areas of cells with anaplasia characterized by enlarged, hyperchromatic nuclei and atypical multipolar mitotic figures. The tumor lacked features of juvenile granulosa cell tumor or microscopically recognizable Sertoli-cells/tubules or Leydig cells. The tumor cells were strongly positive for vimentin and nuclear p53. Rare cells showed weak staining for desmin. Muscle specific actin and MyoD1 were negative. Inhibin was negative. She was treated with vincristine, actinomycin D and cyclophosphamide. Surveillance evaluations showed no evidence of disease until 4 years following her original diagnosis when she presented with amenorrhea and an elevated testosterone. Imaging showed a right sided ovarian mass. Pathology showed an intermediately differentiated SLCT (Fig. 2) . Surgical staging showed tumor adherent to the uterus (International Federation of Gynecology and Obstetrics Stage IIA). She was treated with six cycles of cisplatin, etoposide and bleomycin chemotherapy. Followup radiographic studies showed no evidence of recurrent disease but noted two renal cysts. She remains alive and well 15 years following the diagnosis of undifferentiated sarcoma and 12 years following diagnosis of SLCT. Family history is negative for malignancy.
Fourteen years following her original diagnosis, she was tested for germline DICER1 mutation. Sequence results showed an intronic mutation in DICER1 (NM_177438. The same germline intronic mutation (c.5096-12 G[A) was detected in a second adolescent with SLCT ( Fig. 3) and two other DICER1-related conditions: a lung cyst and thyroid nodule. Sequencing of this individual's SLCT showed the germline NM_177438.2:c.5096-12G[A and a somatic c.5126A[T; p.Asp1709Val. No TP53 mutations were detected. Family History is notable for hypothyroidism in two first degree relatives and a thyroidectomy for unspecified reasons in a second degree relative. She remains alive and well more than 1 year following diagnosis of SLCT. These two individuals are not known to be related, however, detailed multi-generation pedigrees are not available.
The NM_177438.2:c.5096-12 G[A germline mutation seen in these two patients results in an exact duplication of the six bases at the splice site at the intron 23 and exon 24 junction (Fig. 4) . Predicted improper splicing leads to inclusion of 10 bases of intronic sequence, frameshift and premature truncation of the protein (NP803187.1: p.Asp1699AlaFS*8) disrupting the RNase IIIb domain.
Discussion
Identification of germline DICER1 mutations has significant clinical importance, both for the individual with the mutation indicating risk for other sites of disease, and for relatives and potential offspring who may also carry the mutation. The most urgent clinical relevance is for probands and relatives under the age of 7 years who are at risk for PPB, the most lethal tumor seen within the spectrum of DICER1 related disorders. Early detection and treatment of cystic PPB before transformation into a solid multi patterned sarcoma may positively influence survival and reduce complications of high dose chemotherapy [22] . The finding of an underlying DICER1 mutation also has implications for surveillance for the primary ovarian tumor. In many centers, girls and women with SLCT are followed for 2-5 years following surgery or adjuvant therapy. After that time period, they are presumed to be at low risk for recurrence. Girls and women with DICER1 mutations remain at risk for metachronous ovarian tumors after the usual risk period for recurrence and should be followed with surveillance imaging, usually ultrasound, after the usual period for recurrence has ended. Additional screening recommendations are available at genereviews.org [6] . Genetic counseling is recommended to ensure that options for familial testing and ongoing surveillance are explored.
Intronic mutations have been described in other familial cancer predisposition syndromes including defects in mismatch repair genes and Gorlin syndrome [23] [24] [25] . Intronic mutations may in some cases create a new splice site resulting in incorporation of additional bases with or without shifting of the reading frame. In this example, a new exact replica of the splice site was created 10 bases proximal to the normal splice site. This is a unique finding in our cohort of PPB and OTST Registries. Only 7 of 90 germline mutations in children with PPB were intronic and each of these were within two base pairs of the splice site, the so-called canonical splice site [26] . One caveat to this study is that 12 of 124 patients with PPB did not have detectable germline DICER1 mutations. While we predict that most of those 12 children will have tumor-specific biallelic mutations, we cannot rule out a deep intronic mutation not detected by our sequencing assay. For patients with ovarian SLCT, only preliminary analysis is available at this time. Twenty individuals have tested positive for germline DICER1 mutations. Of these, five have base substitutions involving splice sites; two presented here and three others with mutations in the canonical splice site.
Conclusion
In this report, we describe the finding of a unique intronic mutation in two patients with SLCT, each with additional DICER1-related conditions. This mutation, which affects the splice site was not detected in SNP databases, 1000 genomes or any of the previously reported series or in other patient samples available in the International OTST or PPB Registries. In the ovarian tumors described in this report, an additional somatic mutation was found in the RNase IIIb domain.
Germline DICER1 mutations should be suspected in individuals with a personal or family history of SLCT but also in patients with juvenile granulosa cell tumor and gynandroblastoma or any ovarian stromal tumor or sarcoma and a personal or family history of nodular thyroid disease or thyroid carcinoma or other DICER1 related conditions. Somatic testing of tumor tissue is the most sensitive way to detect DICER1 mutations which may be germline or tumor-specific. When analyzing DICER1 mutations, it is necessary to consider the role of intronic mutations creating nonfunctional DICER1 protein.
